Business
Results of AGM
IXICO plc announced that all resolutions presented at its Annual General Meeting were passed with overwhelming support, including the re-election of directors Bram Goorden, Grant Nash, Mark Warne, Dr Dipti Amin, and Kate Rogers, with over 99.99% of votes cast in favour for each. The re-appointment of auditors Moore Kingston Smith and the allotment of securities also received near unanimous approval, with 100% of votes for the auditors and 100% for the allotment of securities. The resolution to disapply pre-emption provisions passed with 99.79% of votes in favour. The total issued share capital with voting rights as of January 22, 2026, was 92,668,598 ordinary shares. Disclaimer*
About this update from Ixico Plc
23 January 2026 IXICO plc ("IXICO" or the "Company") Results of AGM IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows: RESOLUTION VOTES FOR % VOTES AGAINST % VOTES TOTAL % ISC VOTED VOTES WITHHELD 1 Reports and Accounts 58,472,204 99.99% 6,000 0.01% 58,478,204 63.10 1,700 2a Re-election of Bram Goorden 58,465,677 99.99% 6,600 0.01% 58,472,277 63.10 7,627 2b Re-election of Grant Nash 58,465,677 99.99% 6,600 0.01% 58,472,277 63.10 7,627 2c Re-election of Mark Warne 58,465,677 99.99% 6,600 0.01% 58,472,277 63.10 7,627 2d Re-election of Dr Dipti Amin 58,465,677 99.99% 6,600 0.01% 58,472,277 63.10 7,627 2e Re-election of Kate Rogers 58,465,677 99.99% 6,600 0.01% 58,472,277 63.10 7,627 3 Re-appointment of Moore Kingston Smith Auditors 58,475,004 100.00% 2,800 0.00% 58,477,804 63.10 2,100 4 Allotment of Securities 58,475,336 100.00% 1,800 0.00% 58,477,136 63.10 2,768 5 * Disapply Pre-Emption Provisions 58,354,629 99.79% 122,507 0.21% 58,477,136 63.10 2,768 * Special Resolution For the purposes of section 341 of the Companies Act 2006, IXICO plc's total issued share capital with voting rights as at 6.30pm on 22 January 2026, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 92,668,598 ordinary shares. Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation of the proportion of the votes 'for' and 'against' a resolution. For further information please contact: IXICO plc +44 (0) 20 3763 7499 Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) +44 (0) 20 7220 0500 Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) About IXICO www.IXICO.com IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world. The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's . Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.